Clinical and Genetic Analysis in Pediatric Patients with Multiple Sclerosis and Related Conditions: Focus on DR Genes of the Major Histocompatibility Complex

Aigerim Galym1, Nazgul Akhmetova1, Madina Zhaksybek1, Svetlana Safina1, Margaritha N. Boldyreva2, Farida K. Rakhimbekova3, Zhannat R. Idrissova1, *
1 Asfendiyarov Kazakh National Medical University, Almaty, Kazakhstan
2 Institute of Immunology Academy of Medical Science of Russia, Moscow, Russian Federation
3 Satpaev University, Almaty, Kazakhstan

Article Metrics

CrossRef Citations:
Total Statistics:

Full-Text HTML Views: 827
Abstract HTML Views: 477
PDF Downloads: 240
ePub Downloads: 122
Total Views/Downloads: 1666
Unique Statistics:

Full-Text HTML Views: 351
Abstract HTML Views: 185
PDF Downloads: 186
ePub Downloads: 88
Total Views/Downloads: 810

Creative Commons License
© 2022 Galym et al.

open-access license: This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International Public License (CC-BY 4.0), a copy of which is available at: This license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

* Address correspondence to this author at the Asfendiyarov Kazakh National Medical University, Almaty, Kazakhstan; E-mail:



There are several diseases recognized as variants of MS: post-infectious acute disseminated encephalitis, multiple sclerosis (MS), Rasmussen leukoencephalitis and Schilder's leukoencephalitis and related, but separate neuroimmune condition – Neuromyelitis Devic’s. In Kazakhstan diagnosis of such diseases was rare and immune modified treatment was only admitted after the age of 18. Clinical and immunogenetic study of MS spectrum diseases in Kazakhstan would allow to justify early targeted treatment.


The aim of the study was to investigate genes of the main complex of human histocompatibility (MHC) associated with diseases of MS spectrum in Kazakhstani population.


Complex clinical, neuroimaging and immunogenetic studies were performed in 34 children (24 girls, 10 boys) aged 4 to 18 years. 21 children were diagnosed with MS (11 Kazakh origin and 10 – Russian; 4 boys, 17 girls), 7 with leucoencephalitis (all Kazakh, 5 boys, 2 girls) and 6 with Devic neuromyelitis optica (all Kazakh, 1 boy, 5 girls). Genotyping of HLA DRB1, DQA1, DQB1 genes was performed for all patients.


MS group was characterized by classical relapsing-remitting MS. Predominant haplotype as a linkage complex was DRB1*15:01~DQA1*01:02~DQB1*06:02 in 20 (47.6%) of 42 DR-alleles, in 16 (76.2%) patients. MS relative risk (RR) was 13,36 for ethnic Kazakhs and RR=5,55 in Russians.

Leukoencephalitis had 7 children, with 28.6% mortality rate. The haplotype DRB1*15:01~DQA1*01:02~DQB1*06:02 as a linkage complex was detected 3 patients (4 alleles), RR=5,88.

Devic’s neuromyelitis optica (NMO) clinical course was characterized by fast and prolonged progression. There was predominance of DRB1*14 allele with RR=3,38.


Summarizing, in the Kazakh population the haplotype DRB1*15:01∼DQA1*01:02∼DQB1*06:02 as a linkage complex was associated with prediction to MS and leukoencephalitis, but not to Devic’s NMO. Our study highlights the importance of awareness of MS and related disorders diagnosis which allows to implement early admission of disease-modified treatment in pediatric MS in Kazakhstan.

Keywords: Neuro-immune diseases, Multiple sclerosis, Children, Major histocompatibility complex, Aquaporin, DRB, Genotyping.


Immune-mediated diseases of the central nervous system (CNS) in childhood are a heterogeneous group of rare conditions sharing the inflammatory involvement of the CNS [1]. They include several disorders, such as multiple sclerosis (MS), acute disseminated encephalo-myelitis, Rasmussen encephalitis and neuromyelitis optica (NMO) [2, 3]. Similar to all autoimmune conditions, children with autoimmune neurological disorders are likely to harbor some genetic predisposition in the major histocompatibility complex (MHC). The human leukocyte antigen (HLA class II) is the human version of the MHC, a gene family encoding cell-surface proteins responsible for the regulation of the immune system [2-4]. This HLA class II molecules are coded by DR-genes and expressed on the surface of macrophage (microglia in CNS), defining interaction with CD4+ T-cells during antigen presentation (autoantigen). Surface antigen presentation initiates the immune process, further leading to autoimmune diseases, for example, MS and related disorders. DR-genes (DRB1, DQA1, DQB1 and others) are inherited as a linkage complex, and every gene is coded by 2 alleles (one from parent 1 and one from parent 2).

The majority of studies showed an association of disease appearance with DRB1*15:01~DQA1*01:02~DQB1*06:02 as a linkage complex [4, 5]. In large American studies from pediatric MS centers, it was shown that HLA-DRB*15 and DQA*02 were strongly associated with the pediatric onset of MS [5, 6] and female gender [6]. The haplotype DRB1*15:01 did not influence the clinical severity but predisposed to the chronic, relapsing-remitting course of the disorder [7, 8]. Another study showed that HLA-DRB1*15:01 was equally associated with teenagers and people older than 50 years affected by MS, however, HLA-DRB1*0801 was associated more with elderly age [9]. HLA-DRB1*15:01 is also correlated with more evident, diffuse spinal cord involvement and with higher disability score [10].

Distribution of alleles of MHC genes in different ethnicities varied in dependence on human population history primary due to geography, epidemics and other factors [11, 12]. In a Canadian pediatric cohort, the linked haplotype DRB1*15:01~DQA1*01:02~DQB1*06:02 was strongly associated with the Europeans and less strongly with non-Europeans [7]. Meta-analysis of 9 genotyping studies from China showed that HLA-DRB1*15 was associated with the risk of MS in the Chinese population, but significantly lower in Europeans [13].

Some factors other than HLA genes might direct the course of MS spectrum disorders. For example, in East London, MS risk was lower by 59% in Black and 85% in South Asian populations in comparison with English [14]. According to the study, Asian risk of MS is 80% lower than Caucasian. The incidence rate of MS in Japan increased from 1986 to 2013 from 8.1 to 18.6 cases/100,000 in period 1986-2013, but it is still significantly lower in comparison with European countries with 115 cases/100,000 population in 2015 [15]. The limited data from Kazakhstan showed MS prevalence as 10.1 per 100 000 population, 16.8 in Caucasians, and 4.9 in Asians [16].

Performing MHC class II gene study in Kazakhstan, where the population usually consists of Kazakhs and Russians, who are living in the same geographic environment, is very interesting from a scientific point of view but also has a practical clinical meaning. Currently, standard diagnosis approaches for MS diseases include brain and spinal MRI and additional investigations. Such investigations as oligoclonal bands and neurofilament light protein in CSF, also optical coherence tomography are hard to access in Kazakhstan. Moreover, patients and medical personnel have skepticism toward MS diagnosis. Therefore, the proof of having an immunogenetic predisposition of MCH class II gene status towards MS gives additional verification of the correct diagnosis.

Many environmental factors are important in neuroimmune diseases development [17-20]. A multicenter study in Canadian MS study showed an association among MS with the haplotype HLA-DRB1*1501, vitamin D insufficiency and previous infection with the Epstein-Barr virus (EBV) [20]. Vitamin D plays a protective role in the disease progression, as it can alter HLA DR autoantigen expression and presentation [21]. In Japan, MS was associated with obesity, smoking and specific dietary habits [22]. Recent data illustrated that immunopeptidomes coded by HLA-DR15 reproduce molecular mimicry with EBV triggering MS development [23]. HLA-”humanized” mice showed that the most prominent encephalitogenic target antigens implicated in human MS were determined by DQB1*06:02, rather than by the DRB1*15:01 [24-27].

Child neuroimmune diseases consist of postinfection, para-infection, inflammatory, demyelinated and sometimes brain necrotizing conditions with heterogeneous pathobiological mechanisms and clinical manifestations [28]. Differential diagnosis includes genetics (immunogenetics), biomarkers, high-resolution MRI, and ELISA or PCR for etiological (viruses) diagnosis [28-32]. Example of a relatively benign MS spectrum disease is acute disseminated encephalomyelitis (ADEM) [32, 33]. One of the rare, but extremely severe forms of the neuroimmune disease is Rasmussen Encephalitis. It is characterized by hemispheric autoimmune inflammation, triggered by viruses, with progressive seizures and brain hemiatrophy outcomes [34, 35]. There is no proved treatment for this disease, anti-TNF agents as Rituximab and intravenous immunoglobulin were used with some success [36]. However, the only proven treatment for termination of progressive, serial seizures is subtotal hemispherectomy [37].

Study of 31 Japanese patients showed an association of postinfection necrotizing encephalopathy with DRB1*09:01 and DQB1*03:03 [38]. Korean study of the disease determined encephalopathy affecting the bilateral thalami, pons, and midbrain in a symmetrical pattern; hemorrhage was in half of the patients and severe neurological deficits in 80% of infants [39].

One of the rarest and severe neuroimmune conditions is Devic’s neuromyelitis optica (NMO). The disease has a severe course with frequent relapses and rapid disability, usually unreversible neurological deficit, causing blindness in more than half of cases and often wheelchair assistance [40-43]. Prevalence and morbidity of NMO in Korean cohort were 2.56 and 0.73 per 100000 accordingly in 2010-2016 [43]. Previously NMO was considered as an MS variant [44, 45], but detection of specific anti-AQ4 antibodies and irreversible blindness proved NMO as separate disease [46-53]. The specific hallmark of the disease is MRI picture of longitudinally extensive transverse myelitis, which is never seen in MS [49, 50]. The anti-Aquaporine-4 (AQP4) antibodies are very specific for NMO, but in 25% of cases, anti-Myelin oligodendrocyte glycoprotein (MOG) antibodies [54, 55] are seen. Some biomarkers are also associated with NMO (glial fibrillary acidic protein and others) [56].

The treatment of NMO should be aggressive to stop progression. Usually steroids, plasma exchange, and intravenous immunoglobulin in high doses or subcutaneous immunoglobulin for long time are used. Immunodepressants are often used too. Nevertheless, there is no distinct effective therapy for NMO [40, 57].

In Kazakhstan, there is limited data about the prevalence of neuroimmune disorders in children. A single study showed that the general prevalence of pediatric MS was approximately 10.1 per 100 000 people. The male to female ratio was 1:2.5 [16]. DR-gene panel helps verify diagnosis of MS and related conditions, especially in pediatric patients and in cases when immune methods are not available in clinical practice (oligoclonal bands in CSF, etc.).

The aim of this study was to investigate whether genetic variants in the MHC region show an association with MS or other pediatric neuroimmune disorders in Kazakh population.


All pediatric patients with a verified diagnosis of MS-spectrum disorder hospitalized at the Aksai Clinic, Kazakh National Medical University between 2015 and 2021 were included in this study. Clinical, neuroimaging and immunological investigations were performed for all of them. The study was conducted after the approval of the Ethical Committee of Kazakh National Medical University (n. 208, 29.04.2015 and n. 11, 23.10.2020). Parents of all patients provided the informed consent document.

Overall, 34 children (24 girls, 10 boys) with demyelination of the central nervous system aged 4 to 18 years were enrolled. 21 children were diagnosed with MS (11 Kazakh origin and 10 – Russian; 4 boys, 17 girls), 7 with leucoencephalitis (all Kazakh, 5 boys, 2 girls) and 6 with Devic’s neuromyelitis optica (all Kazakh, 1 boy, 5 girls).

The diagnosis of MS and other neuroimmune disorders was performed according to the latest version of McDonald's criteria [58]. Brain MRI was performed in all children with a 1.5 Tesla MRI scanner (Simens 1.5 Tesla Aero, 16 channels apparatus, Germany) in FLAIR regime, with gadolinium contrast. In patients with NMO, the amount of antibody to aquaporin 4 in the serum was tested by ELISA kits (Anti-AQP4 Kit, AEA582Hu, Cloud-Clone Corp., USA).

The genotyping of HLA loci was performed at the Atchabarov Institute for Basic and Applied Biomedical Research (Kazakhstan), after approval of the relevant Ethics Committee (n. 208, 29/04/2015). Data from the healthy Kazakh population (Kazakh Normal) were obtained from Kuranov et al. [59] and healthy Russian population (Russian Normal) from Boiko et al. [60]. The DNA was isolated according to a standard protocol [60]. The HLA-DRB1, HLA-DQA1, and HLA-DQB1 loci were detected by real-time PCR. The following specificities were tested: DRB1 * 01, 03, 04, 07, 08, 09, 10, 11, 12, 13, 14, 15, 16; DQA1 * 01:01, 01:02, 01:03, 02:01, 03:01, 04:01, 05:01, 06:01; DQB1 * 02, 03:01, 03:02, 03:04, 03:05, 04:01/04:02, 05:01, 05:02/05:04, 05:03, 06:01, 06:02-8. The number of alleles is equal to twice the number of patients.

2.1. Statistical Analysis

Qualitative data were presented as absolute numbers and percentages. Genetic data were compared between children with neuroimmune disorders and healthy populations using the Fisher test. A p-value < 0.01 was considered statistically significant. The relative risk (RR) was also calculated. Statistical analysis was performed by SPSS (version 16). The genetic data (group of alleles) of our patients and the population standard were calculated by direct counting and compared using the χ2 criterion in the Fisher test for small samples and relative risk was calculated (RR), p<0.01 was considered significant.


Overall, 34 children (24 females and 10 males) with neuroimmune disorders of central nervous system were enrolled. They were aged between 4 and 18 years old. Among them, 21 children were diagnosed with MS (11 Kazakh origin and 10 – Russian; 4 boys, 17 females and 4 males), 7 children with leucoencephalitis (all Kazakh origin; 2 females and 5 males) and 6 children with NMO (all Kazakh, 5 females and 1 male).

3.1. Clinical Characteristics of Children with MS

Out of the 21 children with MS, a total of 11 children were of Kazakh origin, while 10 children were Russians. The average age of debut was 14.3 ± 2.7 years old. They were affected by relapsing-remitting MS. There were 6 out of 21 patients (28.6%) who experienced 2 relapses, 8 out of 21 (38.1%) had 3 relapses, 4 out of 21 (19.05%) had 4 relapses and a single patient (4.8%) had 5 exacerbations. The mean number of relapses was 3.15 ± 1.09.

The average number of exacerbations during the follow-up period was 3.5±0.85. The Expanded Disability Status Scale (EDSS) mean value at the baseline was 1.62 ± 0.6. After 2-4 years, the mean value increased (2.05 ± 0.71, p = 0.001).

Symptoms at the debut were mainly optic neuritis (17 out of 21 children, 80.9%), limb ataxia (13 out of 21 children, 61.9%) and truncal ataxia (11 out of 21 children, 52.4%). After 2-4 years, the most common symptoms were limb ataxia (15 out of 21 children, 71.4%), pyramidal symptoms (14 out of 21 children, 66.7%) and truncal ataxia (12 out of 21 children, 57.1%). Mean number of relapses was 3.15±1.09; in 6 of 21 patients (28.6%) had 2 relapses, 8 of 21 (38.1%) children had 3 relapses, and 4 of 21 (19.05%) patients had 4 relapses and 1 (4.8%) had 5 exacerbations. Data are presented in Table 1.

Table 1. Clinical characteristics of children with MS (n = 21).
Clinical Symptoms Debut After 2-4 Years p-Value
EDSS (Mean ± standard deviation, M±m) 1.62 ± 0.6 2,05 ± 0.71 0.001
Number of relapses (M±m) - 3.15 ± 1.09 0.001
Optic neuritis 17 out of 21 (80.9%) 11 out of 21 (52.4%)
Strabismus 3 out of 21 (14.3%) 1 out of 21 (4.8%)
Limb ataxia 13 out of 21 (61.9%) 15 out of 21 (71.4%)
Truncal ataxia 11 out of 21 (52.4%) 12 out of 21 (57.1%)
Pyramidal symptoms 10 out of 21 (47.6%) 14 out of 21 (66.7%)
Hemiparesis 7 out of 21 (33.3%) 9 out of 21 (42.9%)
Paraparesis 3 out of 21 (14.3%) 4 out of 21 (19.1%)
Hyperkinesis 2 out of 21 (9.5%) 1 out of 21 (4.8%)
Mood disturbances 6 out of 21 (28.6%) 11 out of 21 (52.4%)
Mild cognitive dysfunction 0 2 out of 21 (9.5%)
Table 2. Brain MRI findings in children with MS.
MRI T2-Active Lesions in the Brain, Number of Children (%) Gadolinium Positive Lesions in the Brain, Number of Children (%) T2-Active Lesions in the Spinal Cord, Number of Children (%)
Debut 21 (100%) 9 (42.9%) 2 (9.5%)
After 2 – 4 years 19 (90.5%) 8 (38.1%) 5 (23.8%)

Brain MRI was performed on all 21 children. All of them showed T2-active periventricular and subcortical lesions after the first attack. Regarding gadolinium positive lesions, they were diagnosed in 9 out of 21 children (42.9%). After 2-4 years, T2-active lesions were diagnosed in the brain of 19 children (90.5%) while gadolinium positive lesions were seen in 8 children (38.1%). Spinal MRI showed T2-active lesions in 2 children (9.5%) at the debut and in 5 children (23.8%) after 2-4 years (Table 2).

As an example, MS in one girl with severe MS (Picture 1) and with another girl with less progressive MS (Picture 2).

3.2. Clinical characteristics of children with leukoencephalitis

Of the seven children with leukoencephalitis, 4 suffered from Schilder’s type encephalitis, 2 from Rasmussen encephalitis and one suffered from multiphasic disseminated encephalomyelitis (Table 3). At the onset of the disease, the age was between 3 and 12 years (mean 8±4.2 years). Hyperthermia and drowsiness were diagnosed in all children with leukoencephalitis. Five children (71.4%) manifested headache and vomiting, while 3 children (42.9%) showed epileptic seizures (Table 3). One boy, who started the illness at 3 years old, had anamnesis of measles at 6 months (he died after 2,5 years because of the progression of the disease), so this likely was subacute sclerosing panencephalitis (SSPE); the other 4-years girl before the disease’s had the tick bite, and anti-togavirus IgG antibodies (she died after 3 years). In 2 children (boys) in anamnesis had perinatal persisted CMV infection, then after 5 years of age they presented with leukoencephalitis. The remaining 3 children during the debut of the disease were >10 years old and 2-4 weeks before the onset they had an upper respiratory viral infection.

Fig. (1). MRI after clinical debut of 14-years girl with doubled DR*15 allele (homozygote) with T2-spinal active lesion (A) and Gd+ active lesion on brain MRI (B).

Fig. (2). A) Brain MRI 2015 – MS debut in 17-years girl (DR*04 and DR*07 of DRB1 gene). B) Increasing in number and volume of periventricular lesions on 2019 MRI, but with comparatively slow progression

Table 3. Clinical characteristics of children with leukoencephalitis.
Clinical Symptoms Debut, Number of Children (%) After 2-4 Years, Number of Children (%)
Hyperthermia 7 out of 7 (100%) 2 out of 7 (28.6%)
Drowsiness 7 out of 7 (100%) 1 out of 7 (14.3%)
Headache 5 out of 7 (71.4%) 1 out of 7 (14.3%)
Epileptic seizures 3 out of 7 (42.9%) 2 out of 7 (28.6%)
Tetraparesis 1 out of 7 (14.3%) 1 out of 7 (14.3%)
Hemiparesis 1 out of 7 (14.3%) 1 out of 7 (14.3%)
Diffuse hypotonia 2 out of 7 (28.6%) 2 out of 7 (28.6%)
Hyperkinesis 2 out of 7 (28.6%) 2 out of 7 (28.6%)
Table 4. Aquaporin-4 antibodies in children with NMO.
Age of Debut Gender Aquaporin 4 Antibody (Normal < 1:10 Dilution of Serum)
At the Debut After 1 Year After 2-3 Years
1 12 Female < 1:160 < 1:80 < 1:20
2 10 Female < 1:80 < 1:40 < 1:80
3 11 Female < 1:80 < 1:40 < 1:40
4 11 Female < 1:80 < 1:40 < 1:40
5 9 Male < 1:80 < 1:80 < 1:20
6 9 Female < 1:80 < 1:40 < 1:40

All children were treated with immunotherapy with intravenous IgG immunoglobulins and methylprednisolone every 2-3 months. Brain MRI showed T2-active lesions in all children, but not gadolinium positive lesions. After 4 years, one child developed symptomatic epilepsy, 3 children showed chronic fatigue, and 2 children died.

3.3. Clinical characteristics of children with neuromyelitis optica

In 6 children, the diagnosis of NMO was confirmed by the presence of serum AQP-4 autoantibodies, which were measured in the dilution of serum. Positive reference is more than 1:10 dilution, so here the maximum level was 1:160, the minimum - 1:20 (Table 4). Within the time, after one year, and after 2-3 years, all children, except one, showed reduced levels of autoantibodies, but anti-AQP-4 level did not achieve normal level (<1:10).

The clinical characteristics of children with NMO (Table 5) were distinguished by a significant vision loss, reflected in a distinct decrease of retinal nerve fiber layer (RNFL) thickness (p = 0.01). Moreover, there was an increase in neurological deficits, including paraparesis, seizures and urinary hesitancy.

Fig. (3A). A) MRI of the spinal cord, 12-years girl with NVO Devic and inflammatory lesion on the C8-Th1, 2 levels in 2019 at the debut of NMO

The spinal MRI performed in children with NMO showed longitudinal tranversus cervical and thoracic spinal demyelination. In Picture 3 it is shown dynamics of the spinal MRI of girl Zh. B. 2007 year of birth, with progressive loss of vision and spinal cord atrophy and severe paraparesis with urinary incontinence due to the NMO autoimmune necrotic process.

3.4. Genotyping of HLA loci

The results of genotyping for the genes of HLA loci in 21 children with MS (17 females and 4 males) are presented in Table 6. In Table 7, the children with MS are compared with a healthy population of Kazakhs and Russians.

Fig. (3B). B) MRI of the spinal cord, the same girl with NVO Devic, inflammatory lesion on the Th1-Th12 and pronounced atrophy on Th1-Th4 levels in 2020 (1 year 10 months after the debut of NMO).

Table 5. Clinical characteristics of children with NMO.
Clinical Characteristics Debut After 2-4 Years p-Value
EDSS score (Mean ± standard deviation, M±m) 2.7 ± 2.1 4.2 ± 2.1 0.01
Loss of vision field (in % from normal volume of vision) center, 30% center, 67%
Right, 34% Right, 71%
Average RNFL total thickness (µm) center, 84.4 ± 34.2 center, 69.2 ± 26.2 0.01
Right, 76.8 ± 40.9 Right, 71.0 ± 38.0 0.01
Hemiparesis 3 out of 6 3 out of 6
Paraparesis 2 out of 6 3 out of 6
Epileptic seizures - 1 out of 6
Urinary hesitancy - 1 out of 6
Mood disturbances 1 out of 6 3 out of 6
Cognitive dysfunction 1 out of 6 2 out of 6
Table 6. Genotyping of HLA loci in children with MS.
Order Number of Patient Age of Onset Gender DRB1 Allele DQA1 Allele DQB1 Allele
1 12 Male 10 15 01:01 01:02 05:01 06:02-8
2 14 Male 09 14 03:01 01:01 03:03 05:03
3 16 Female 15 15 01:02 01:02 06:02-8 06:02-8
4 13 Female 15 15 01:02 01:02 06:02-8 06:02-8
5 17 Female 04 07 02:01 03:01 02 04:01/04:02
6 16 Female 13 15 01:02 01:03 06:02-8 06:02-8
7 16 Female 12 15 01:02 05:01 03:01 06:02-8
8 17 Female 03 15 05:01 01:02 02 06:02-8
9 14 Female 13 15 01:02 01:02 06:02-8 06:02-8
10 18 Female 03 11 05:01 05:01 02 03:01
11 14 Female 09 15 03:01 01:02 03:03 06:02-8
12 15 Female 04 15 03:01 01:02 03:02 06:02-8
13 17 Female 10 15 01:01 01:02 05:01 06:02-8
14 18 Male 03 11 05:01 05:01 02 03:01
15 11 Female 11 15 05:01 01:02 03:01 06:02-8
16 13 Female 07 15 02:01 01:02 02 06:02-8
17 12 Female 15 15 01:02 01:02 06:02-8 06:02-8
18 11 Female 09 15 03:01 01:02 03:03 06:02-8
19 14 Male 07 15 01:03 02:01 02 06:02-8
20 14 Female 09 15 03:01 01:02 03:03 06:02-8
21 15 Female 08 15 04:01 04:01 04:01/04:02 06:02-8
Table 7. Genotyping results of children with MS compared with healthy Kazakhs and Russian populations.
Alleles Kazakh Normal Russian Normal Children with MS
DRB1 % abs % abs % abs
*01 4.5 14 8.15 22 0 0
*03 13.7 43 7.88 21 7.14 3
*04 8.1 25 12.96 35 4.76 2
*07 13.1 41 13.33 36 7.14 3
*08 3.7 11 2.59 7 2.38 1
*09 4.8 15 0.37 1 9.52 4
*10 1.2 4 1.48 4 4.76 2
*11 11.9 37 13.7 37 7.14 3
*12 2.5 8 3.7 10 2.38 1
*13 17.2 54 12.96 35 4.76 2
*14 12.9 40 2.59 7 2.38 1
*15 6.3 20 14.07 38 47.6 20
*16 0.6 2 6.3 17 0
Number of alleles 314 270 42
RR of DRB1*15 13.36 5.55
p-value < 0.001 < 0.001
χ2 63.2 27.0

As shown in Tables 6 and 7, the HLA-DR15 haplotype genes were detected in linkage disequilibrium (DRB1*15 ~DQA1*01:02~ DQB1*06:02) in 16 (76.2%) children with MS, or in 20 (47,6%) alleles. In comparison, the same pattern was seen in 6.3% of Kazakh Normal and 14.0% of Russian Normal. The relative risk (RR) for developing MS was more than 13 times higher than healthy Kazakhs (χ2 = 63.2; p < 0.001) and more than 5 times higher than healthy Russians (χ2 = 27.0, p < 0.001).

Children with DR15 (13 heterozygotes and 3 homozygotes) were predominantly females (15 out of 16 allele carriers). At the age of onset, they were younger (14.1 vs. 16.2 years old) Table 8. However, the difference was not statistically significant (p < 0.05). Three homozygous Russian girls manifested the disease at the age of 11, 12 and 16 years old. They showed a classical MS course with EDSS progression and distinct MRI features (Figs. 1-3).

The results of genotyping for the genes of HLA loci in 7 children with leukoencephalitis (2 females and 5 males) are presented in Table 9. The HLA-DR15 haplotype genes were detected in 3 out of 7 children and in 4 out of 14 alleles (28.6%) (RR = 5.88, χ2 = 9.74, p = 0.01 compared with Russian Normal). The allele DRB1*16 was found in two children (14.3%) (RR = 26, χ2 = 20.7, p = 0.01 compared with Kazakh Normal).

Table 8. Genotyping characteristics of children with MS.
Feature HLA-DR15 allele Other alleles
Number of mails 1 3
Number of females 15 2
Mean age (years) 14.1±2 16.2±2.05
p-value (age) 0.045
p-value (gender) 0.046
Table 9. Genotyping of HLA loci in children with leukoencephalitis.
Order Number of Patient Gender DRB1 Allele DQA1 Allele DQB1 Allele
1 Male 04 15 1:02 3:01 3:02 06:02-8
2 Female 15(02) 16(02) 01:02 01:02 06:02-8 05:02/4
3 Female 11(05) 15(02) 05:01 01:02 03:01 06:02-8
4 Female 09 11 03:01 5:01 3:02 3:03
5 Male 8 15 1:02 4:01 04:01/04:02 06:02-8
6 Female 03 10 0:501 01:01 02 05:01
7 Female 12 16 1:02 5:01 3:01 05:02/05:04

In children with NMO (5 females and 1 male), the HLA-DR15 haplotype genes were found in only one heterozygous child (16.7%) (RR = 2.94, χ2 = 1.02, p = 0.3 compared with Kazakh Normal) (Table 10).

Table 10. Genotyping of HLA loci in children with NMO.
Order number of patient Gender DRB1 Allele DQA1 Allele DQB1 Allele
1 Female 08 12 04:01 06:01 03:01 04:01/04:02
2 Female 01 13 01:01 01:02 05:01 06:02-8
3 Female 11 14 03:01 05:01 03:01 03:01
4 Female 14 14 01:01 01:01 05:03 05:02/4
5 Female 03 14 01:01 05:01 02 05:02/05:04
6 Male 09 15 01:02 03:01 03:03 06:02-8

The DRB1*14 allele was present in 66% of children with NMO (RR = 3.38, χ2 = 4.09, p = 0.05 compared with healthy Kazakhs).


In this study, we showed that children with MS group were characterized by a relapsing-remitting MS, with an EDSS progression from 1.62±0.6 to 2.05±0.71 in 2-4 years after debut. Primarily, about 90% of them were diagnosed with ADEM, as described in studies by other authors [12, 13]. The most prominent syndromes at debut were optic neuritis (80.9%) and cerebellar ataxia (61,9%), which were partly reversible.

Considering the HLA loci, there was a predominance of the haplotype DRB1*15 ~DQA1*01:02~ DQB1*06:02 as linkage complex. This pattern was detected in 20 (47.6%) of 42 DR-alleles, and in 16 (76.2%) patients from the investigation group. In comparison, in Kazakh Normal population, this haplotype was seen in 6.3% of investigated DR-alleles, in Russian normal – in 14.07%. In our cohort of children, the relative risk (RR) for developing MS was 13.4 times higher in Kazakh individuals and 5.6 times higher in Russian individuals. The haplotypes DRB1*15 ~DQA1*01:02~ DQB1*06:02 carriers were mostly female (15 from 16) and had a younger age of onset (14.1±2 against 16.2±2.05 years), similar to literature [5-7, 61-63]. In our previous studies, the haplotypes DRB1*15, DQA1*01:02 and DQB1*06:02 were detected in 32.2% of analyzed alleles [64]. This difference (47.6% vs. 32.2%) is related to the pool of data (number of enrolled patients). In the previous study, all children with a neuroimmune disorder were pooled together, MS and related conditions. In this study, we analyzed patients according to their exact clinical diagnoses.

Other numerous studies found that the haplotype DRB1*15~DQA1*01:02~ DQB1*06:02 was highly frequent in MS [2-5]. However, in African-Brazilian children with MS, the strongest association was observed with DQB1*06:02 rather than DRB1*15 [65]. Some authors suggested that these haplotypes did not predict the clinical course of MS [4]. Nevertheless, we described that the presence of DRB1*15 negatively influenced the follow-up of MS, as described by other authors, especially concerning worse brain MRI changes [6, 8, 66]. Varying MS diagnosis criteria, such as CSF studies and optical coherence tomography, are of limited access in Kazakhstan. Genetic studies of MCH class II genes help verify the diagnosis of MS spectrum diseases, which corresponds well to the findings of other MS study groups and help estimate the risks and evaluate the course of the diseases with increased accuracy.

In children with leukoencephalitis, the presence of haplotype DRB1*15~DQA1*01:02~ DQB1*06:02 was detected in 28.6% with RR=5,88. In Japan's study of post-viral acute necrotizing encephalopathy, the alleles DRB1*09:01 and DQB1*03:03 were approximately twice as frequent as controls [38]. Thereby, in our study, post-viral leucoencephalitis Rasmussen type in immune mechanism was closer to MS.

Children with NMO were characterized by vision loss and neurological deficits, including spastic hemiparesis and paraparesis. The genotyping analysis showed a high presence of DRB1*14 (seen in 66% of children with NMO with RR = 3.38), this allele has already been associated with systemic vasculitis in Japanese patients [68, 69]. In Muslim Arabs from Israel, individuals with anti-AQP4 NMO were characterized by a high presence of DQB1*04:02 and DRB1*10 [70]. Spanish NMO patients had DRB1*010 allele association compared with MS; further, these patients had DRB1*03 allele association in comparison with healthy controls [71]. According to data, genetically NMO is closer to systemic immune diseases rather than MS.


Thus, this study showed the appearance of haplotype DRB1*15~DQA1*01:02~ DQB1*06:02 in Kazakhstan patients as one of the relevant diagnosis criteria for MS and related conditions which is described in numerous MS DR-gene studies [4-8]. This helps Kazakh neurology specialists and parents of patients to have an accurate diagnosis and admit target immune disease modified treatment (beta-interferon, Capaxon and others) early.

Currently, in our country, such kind of treatment is available through mandatory medical insurance from the age 18. Usually, the start of treatment is delayed by 6-9 months due to bureaucratic procedures. Our study shows the need to initiate such treatment as soon as possible after establishing the diagnosis in children and adolescents because it is known that axonal losses and reduction of brain tissue volume in patients with child MS onset occur early and in bigger volumes till a certain age (for example by 40 years) [3, 5].

Early diagnosis and timely target treatment prevent further brain volume loss and irreversible EDSS alterations. Further study would admit more patients and incorporate deep neurological and immunological studies of MS and related conditions.


CNS = Central Nervous System
NMO = Neuromyelitis Optica


The study was conducted after approval of the Ethical Committee of Kazakh National Medical University (n. 208, 29.04.2015 and n. 11, 23.10.2020).


No animals were used for studies that are the basis of this research. All the humans used were in accordance with the Helsinki Declaration of 1975, as revised in 2013.


Parents of all patients provided the informed consent document.


STROBE guidelines were followed.


Not applicable.


This research was financially supported by the grant AP09562785 (Creation and implementation of a modern system of diagnostics, monitoring and treatment of neuroimmune orphan diseases in children in the Republic of Kazakhstan, registration number 0121РК00600, provided by the Ministry of Education, Republic of Kazakhstan).


The authors declare no conflicts of interest.


We express our sincere gratitude to Dr. A. B. Kuranov and the Research Institute of Fundamental and Applied Medicine named after B. Atchabarov for the help and support received in conducting the study. We would like to thank TopEdit ( for its linguistic assistance during the preparation of this manuscript.


[1] Ness JM, Chabas D, Sadovnick AD, Pohl D, Banwell B, Weinstock-Guttman B. International Pediatric MS Study Group. Clinical features of children and adolescents with multiple sclerosis. Neurology 2007; 68(16 Suppl 2): 37-45.
[2] Alroughani R, Boyko A. Pediatric multiple sclerosis: A review. BMC Neurol 2018; 18(1): 27.
[3] Chitnis T. Pediatric demyelinating diseases. Continuum (Minneap Minn) 2013; 19(4 Multiple Sclerosis): 1023-45.
[4] Hollenbach JA, Oksenberg JR. The immunogenetics of multiple sclerosis: A comprehensive review. J Autoimmun 2015; 64: 13-25.
[5] Gianfrancesco MA, Stridh P, Shao X, et al. Network of Pediatric Multiple Sclerosis Centers. Genetic risk factors for pediatric-onset multiple sclerosis. Mult Scler 2018; 24(14): 1825-34.
[6] Hensiek AE, Sawcer SJ, Feakes R, et al. HLA-DR 15 is associated with female sex and younger age at diagnosis in multiple sclerosis. J Neurol Neurosurg Psychiatry 2002; 72(2): 184-7.
[7] Disanto G, Magalhaes S, Handel AE, et al. Canadian Pediatric Demyelinating Disease Network. HLA-DRB1 confers increased risk of pediatric-onset MS in children with acquired demyelination. Neurology 2011; 76(9): 781-6.
[8] Cournu-Rebeix I, Génin E, Leray E, et al. HLA-DRB1*15 allele influences the later course of relapsing remitting multiple sclerosis. Genes Immun 2008; 9(6): 570-4.
[9] Qiu W, Wu JS, Castley A, et al. Clinical profile and HLA-DRB1 genotype of late onset multiple sclerosis in Western Australia. J Clin Neurosci 2010; 17(8): 1009-13.
[10] Qiu W, Raven S, James I, et al. Spinal cord involvement in multiple sclerosis: A correlative MRI and high-resolution HLA-DRB1 genotyping study. J Neurol Sci 2011; 300(1-2): 114-9.
[11] Roberts-Thomson PJ, Roberts-Thomson RA, Nikoloutsopoulos T, Gillis D. Immune dysfunction in Australian Aborigines. Asian Pac J Allergy Immunol 2005; 23(4): 235-44.
[12] Buhler S, Sanchez-Mazas A. HLA DNA sequence variation among human populations: Molecular signatures of demographic and selective events. PLoS One 2011; 6(2): e14643.
[13] Qiu W, James I, Carroll WM, Mastaglia FL, Kermode AG. HLA-DR allele polymorphism and multiple sclerosis in Chinese populations: A meta-analysis. Mult Scler 2011; 17(4): 382-8.
[14] Albor C, du Sautoy T, Kali Vanan N, Turner BP, Boomla K, Schmierer K. Ethnicity and prevalence of multiple sclerosis in east London. Mult Scler 2017; 23(1): 36-42.
[15] Zhang GX, Carrillo-Vico A, Zhang WT, Gao SS, Ayuso GI. Incidence and prevalence of multiple sclerosis in China and other Asian countries. Neurologia 2020; S0213-4853(20): 30269-.
[16] Khaibullin TN, Kirillova EV, Bikbaev RM, Boyko AN. Kliniko-épidemiologicheskie kharakteristiki rasseiannogo skleroza i optikoneĭromielita v Tsentral'noĭ Azii [Clinical-epidemiological characteristics of multiple sclerosis and neuroopticomyelitis in the Central Asia]. Zh Nevrol Psikhiatr Im S S Korsakova 2019; 119(2. Vyp. 2): 12-7.
[17] Ascherio A, Munger KL. Environmental risk factors for multiple sclerosis. Part I: The role of infection. Ann Neurol 2007; 61(4): 288-99.
[18] Ascherio A, Munger KL. Environmental risk factors for multiple sclerosis. Part II: Noninfectious factors. Ann Neurol 2007; 61(6): 504-13.
[19] Kakalacheva K, Lünemann JD. Environmental triggers of multiple sclerosis. FEBS Lett 2011; 585(23): 3724-9.
[20] Kakalacheva K, Münz C, Lünemann JD. Viral triggers of multiple sclerosis. Biochim Biophys Acta Mol Basis Dis 2011; 1812(2): 132-40.
[21] Banwell B, Bar-Or A, Arnold DL, et al. Clinical, environmental, and genetic determinants of multiple sclerosis in children with acute demyelination: A prospective national cohort study. Lancet Neurol 2011; 10(5): 436-45.
[22] Handunnetthi L, Ramagopalan SV, Ebers GC. Multiple sclerosis, vitamin D, and HLA-DRB1*15. Neurology 2010; 74(23): 1905-10.
[23] Sakoda A, Matsushita T, Nakamura Y, et al. Environmental risk factors for multiple sclerosis in Japanese people. Mult Scler Relat Disord 2020; 38: 101872.
[24] Wang J, Jelcic I, Mühlenbruch L, et al. HLA-DR15 Molecules Jointly Shape an Autoreactive T Cell Repertoire in Multiple Sclerosis. Cell 2020; 183(5): 1264-1281.e20.
[25] Kaushansky N, Ben-Nun A. DQB1*06:02-Associated Pathogenic Anti-Myelin Autoimmunity in Multiple Sclerosis-Like Disease: Potential Function of DQB1*06:02 as a Disease-Predisposing Allele. Front Oncol 2014; 4: 280.
[26] Ayrignac X, Carra-Dallière C, Labauge P. Atypical inflammatory demyelinating lesions and atypical multiple sclerosis. Rev Neurol (Paris) 2018; 174(6): 408-18.
[27] Solomon AJ, Bourdette DN, Cross AH, et al. The contemporary spectrum of multiple sclerosis misdiagnosis. Neurology 2016; 87(13): 1393-9.
[28] Wells E, Hacohen Y, Waldman A, et al. attendees of the International Neuroimmune Meeting. Neuroimmune disorders of the central nervous system in children in the molecular era. Nat Rev Neurol 2018; 14(7): 433-45.
[29] Krupp LB, Tardieu M, Amato MP, et al. International Pediatric Multiple Sclerosis Study Group. International Pediatric Multiple Sclerosis Study Group criteria for pediatric multiple sclerosis and immune-mediated central nervous system demyelinating disorders: Revisions to the 2007 definitions. Mult Scler 2013; 19(10): 1261-7.
[30] Greenlee JE. Encephalitis and postinfectious encephalitis. Continuum 2012; 18(6 Infectious Disease): 1271-89.
[31] Britton PN, Dale RC, Blyth CC, et al. Causes and Clinical Features of Childhood Encephalitis: A Multicenter, Prospective Cohort Study. Clin Infect Dis 2020; 70(12): 2517-26.
[32] Cordier F, Velthof L, Creytens D, Van Dorpe J. Acute Disseminated Encephalomyelitis (ADEM): A Demyelinating Disease with Specific Morphological Features. Int J Surg Pathol 2021; 29(4): 392-4.
[33] Reig Sáenz R, Zazo Santidrián C, Martín Medina P, Feliú Rey E, Díaz Barranco M, Plumed Martín L. Evolución clínica de la forma hiperaguda de la encefalomielitis aguda desmielinizante. An Pediatr (Barc) 2013; 78(4): 234-40.
[34] Varadkar S, Bien CG, Kruse CA, et al. Rasmussen’s encephalitis: Clinical features, pathobiology, and treatment advances. Lancet Neurol 2014; 13(2): 195-205.
[35] Cay-Martinez KC, Hickman RA, McKhann GM II, Provenzano FA, Sands TT. Rasmussen Encephalitis: An Update. Semin Neurol 2020; 40(2): 201-10.
[36] Orsini A, Foiadelli T, Carli N, et al. Rasmussen’s encephalitis: From immune pathogenesis towards targeted-therapy. Seizure 2020; 81: 76-83.
[37] Yamamoto N, Kuki I, Nagase S, et al. Subtotal hemispherotomy for late-onset spasms after anti-myelin oligodendrocyte glycoprotein antibody-positive acute haemorrhagic leukoencephalitis. Epileptic Disord 2021; 23(6): 957-60. Epub ahead of print
[38] Hoshino A, Saitoh M, Miyagawa T, et al. Specific HLA genotypes confer susceptibility to acute necrotizing encephalopathy. Genes Immun 2016; 17(6): 367-9.
[39] Kim JH, Kim IO, Lim MK, et al. Acute necrotizing encephalopathy in Korean infants and children: Imaging findings and diverse clinical outcome. Korean J Radiol 2004; 5(3): 171-7.
[40] Huda S, Whittam D, Bhojak M, et al. Neuromyelitis optica spectrum disorders. Clin Med (Lond) 2019; 19(2): 169-76.
[41] Tillema JM, McKeon A. The spectrum of neuromyelitis optica (NMO) in childhood. J Child Neurol 2012; 27(11): 1437-47.
[42] Asgari N, Owens T, Frøkiaer J, Stenager E, Lillevang ST, Kyvik KO. Neuromyelitis optica (NMO) - An autoimmune disease of the central nervous system (CNS). Acta Neurol Scand 2011; 123(6): 369-84.
[43] Kim JE, Park SH, Han K, Kim HJ, Shin DW, Kim SM. Prevalence and incidence of neuromyelitis optica spectrum disorder and multiple sclerosis in Korea. Mult Scler 2020; 26(14): 1837-44.
[44] Juryńczyk M, Craner M, Palace J. Overlapping CNS inflammatory diseases: Differentiating features of NMO and MS. J Neurol Neurosurg Psychiatry 2015; 86(1): 20-5.
[45] Boiko AN, Guseva ME, Guseva MR, et al. Clinico-immunogenetic characteristics of multiple sclerosis with optic neuritis in children. J Neurovirol 2000; 6(2)(Suppl. 2): S152-5.
[46] Trebst C, Jarius S, Berthele A, et al. Neuromyelitis Optica Study Group (NEMOS). Update on the diagnosis and treatment of neuromyelitis optica: Recommendations of the Neuromyelitis Optica Study Group (NEMOS). J Neurol 2014; 261(1): 1-16.
[47] Bennett JL. Finding NMO: The Evolving Diagnostic Criteria of Neuromyelitis Optica. J Neuroophthalmol 2016; 36(3): 238-45.
[48] Jacob A, McKeon A, Nakashima I, et al. Current concept of neuromyelitis optica (NMO) and NMO spectrum disorders. J Neurol Neurosurg Psychiatry 2013; 84(8): 922-30.
[49] Lu Z, Qiu W, Zou Y, et al. Characteristic linear lesions and longitudinally extensive spinal cord lesions in Chinese patients with neuromyelitis optica. J Neurol Sci 2010; 293(1-2): 92-6.
[50] Tobin WO, Weinshenker BG, Lucchinetti CF. Longitudinally extensive transverse myelitis. Curr Opin Neurol 2014; 27(3): 279-89.
[51] Jarius S, Wildemann B. Aquaporin-4 antibodies (NMO-IgG) as a serological marker of neuromyelitis optica: A critical review of the literature. Brain Pathol 2013; 23(6): 661-83.
[52] Takai Y, Misu T, Takahashi T, Nakashima I, Fujihara K. [NMO spectrum disorders and anti AQP4 antibody]. Brain Nerve 2013; 65(4): 333-43. [NMO spectrum disorders and anti AQP4 antibody].
[53] Zekeridou A, Lennon VA. Aquaporin-4 autoimmunity. Neurol Neuroimmunol Neuroinflamm 2015; 2(4): e110.
[54] Winter A, Chwalisz B. MRI Characteristics of NMO, MOG and MS Related Optic Neuritis. Semin Ophthalmol 2020; 35(7-8): 333-42.
[55] Jarius S, Ruprecht K, Kleiter I, et al. MOG-IgG in NMO and related disorders: A multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome. J Neuroinflammation 2016; 13(1): 280.
[56] Chang KH, Ro LS, Lyu RK, Chen CM. Biomarkers for neuromyelitis optica. Clin Chim Acta 2015; 440: 64-71.
[57] Brod SA. Review of approved NMO therapies based on mechanism of action, efficacy and long-term effects. Mult Scler Relat Disord 2020; 46(102538): 102538.
[58] Thompson AJ, Banwell BL, Barkhof F, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol 2018; 17(2): 162-73.
[59] Kuranov AB, Vavilov MN, Abil’dinova GZh, et al. HLA Class II Genes in the Kazakh population. Immunologiya 2015; 36(3): 132-9.
[60] Boiko AN, Gusev EI, Sudomoina MA, et al. Association and linkage of juvenile MS with HLA-DR2(15) in Russians. Neurology 2002; 58(4): 658-60.
[61] Gontika M, Skarlis C, Artemiadis A, et al. HLA-DRB1 allele impact on pediatric multiple sclerosis in a Hellenic cohort. Mult Scler J Exp Transl Clin 2020; 6(1)
[62] Alcina A, Abad-Grau MM, Fedetz M, et al. Multiple sclerosis risk variant HLA-DRB1*1501 associates with high expression of DRB1 gene in different human populations. PLoS One 2012; 7(1): e29819.
[63] Chao MJ, Barnardo MCNM, Lincoln MR, et al. HLA class I alleles tag HLA-DRB1 * 1501 haplotypes for differential risk in multiple sclerosis susceptibility. Proc Natl Acad Sci USA 2008; 105(35): 13069-74.
[64] Idrissova Z, Kolbaev M, Galym A, Boldyreva M. Predictors of development of juvenile multiple sclerosis in Kazakh population according to the DR-genes of Major Histocompatibility Complex. J Neurol Exp Neurosci 2018; 4(2): 30-5.
[65] Caballero A, Alvés-León S, Papais-Alvarenga R, Fernández O, Navarro G, Alonso A. DQB1*0602 confers genetic susceptibility to multiple sclerosis in Afro-Brazilians. Tissue Antigens 1999; 54(5): 524-6.
[66] Liguori M, Healy BC, Glanz BI, et al. HLA (A-B-C and -DRB1) alleles and brain MRI changes in multiple sclerosis: A longitudinal study. Genes Immun 2011; 12(3): 183-90.
[67] Furukawa H, Kawasaki A, Oka S, et al. Human leukocyte antigens and systemic lupus erythematosus: A protective role for the HLA-DR6 alleles DRB1*13:02 and *14:03. PLoS One 2014; 9(2): e87792.
[68] Furukawa H, Oka S, Kawasaki A, et al. Human Leukocyte Antigen and Systemic Sclerosis in Japanese: The Sign of the Four Independent Protective Alleles, DRB1*13:02, DRB1*14:06, DQB1*03:01, and DPB1*02:01. PLoS One 2016; 11(4): e0154255.
[69] Alonso VR, de Jesus Flores Rivera J, Garci YR, et al. Neuromyelitis Optica (NMO IgG+) and Genetic Susceptibility, Potential Ethnic Influences. Cent Nerv Syst Agents Med Chem 2018; 18(1): 4-7.
[70] Brill L, Mandel M, Karussis D, et al. Increased occurrence of anti-AQP4 seropositivity and unique HLA Class II associations with neuromyelitis optica (NMO), among Muslim Arabs in Israel. J Neuroimmunol 2016; 293: 65-70.
[71] Blanco Y, Ercilla-González G, Llufriu S, et al. HLA-DRB1 en pacientes caucasicos con neuromielitis optica. Rev Neurol 2011; 53(3): 146-52. [HLA-DRB1 typing in Caucasians patients with neuromyelitis optica]. [Spanish.].